Overall, Q1 was another excellent quarter for DOC, but the market continues to show no love for the stock. The market cannot continue to ignore stellar results for much longer.
Definitely cheaper than when I published this article! (sigh) ... Top-line growth and demand has continued to be strong (as I predicted) but I was caught off guard by two main factors which have led to a sharp sell-off in DOC: 1) their unsophisticated tech infrastructure and the lack of disclosure about these issues by the (thankfully) former CEO and 2) difficulties attracting enough GPs to meet patient demand, forcing them to provide lots of GP incentives and impacting gross margins.
Current market cap @ 21.27M (17/1/2023); seems like a solid business and undervalued.
Definitely cheaper than when I published this article! (sigh) ... Top-line growth and demand has continued to be strong (as I predicted) but I was caught off guard by two main factors which have led to a sharp sell-off in DOC: 1) their unsophisticated tech infrastructure and the lack of disclosure about these issues by the (thankfully) former CEO and 2) difficulties attracting enough GPs to meet patient demand, forcing them to provide lots of GP incentives and impacting gross margins.
Thank you!